The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Official Title: A Single Arm, Open-label, Multicenter Phase 2 Study of Regorafenib in Participants Who Have Been Treated in a Previous Bayer-sponsored Regorafenib Study (Monotherapy or Combination Treatment) That Has Reached the Primary Completion Endpoint or the Main Data Analysis, or Has Been Stopped Prematurely.
Study ID: NCT03890731
Brief Summary: The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. Patients participating in this study will be observed to collect information on how safe the drugs are and how this treatment is tolerated.
Detailed Description: The primary objectives of the study are a) to allow patients from Bayer-sponsored trials to continue regorafenib treatment after their respective study has been completed, and b) to further assess the safety of regorafenib. Secondary objective is the documentation of drug tolerability.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Tampa General Medical Group, Tampa, Florida, United States
Eberhard-Karls-Universität Tübingen, Tübingen, Baden-Württemberg, Germany
Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany
A.O.U. Careggi, Firenze, Toscana, Italy
Saiseikai Utsunomiya Hospital, Utsunomiya-shi, Tochigi, Japan
Mount Vernon Hospital, Northwood, , United Kingdom